This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard C. Newton, MD; Joseph L. Jorizzo, MD; Alvin R. Solomon, Jr, MD; Ramon L. Sanchez, MD; Jerry C. Daniels, MD, PhD; John D. Bell, MD; Tito Cavallo, MD

Arch Dermatol. 1986;122(2):170-176.

Abstract
• Eight of ten patients with chronic or subacute cutaneous lupus erythematosus completed 16 weeks of oral isotretinoin therapy (80 mg/day). All eight patients noted an excellent clinical response without significant side effects. (Two patients did not return to initial two-week follow-up.) Peripheral blood B- and T-cell counts were unaffected by therapy. Therapy was associated with resolution of routine histopathologic abnormalities, conversion of abnormal lesional direct immunofluorescence microscopy to normal, normalization of the epidermis on electron microscopy, and reduction of all T cells near the dermoepidermal junction without change in ratio of T-helper/inducer cells to T-suppressor/cytotoxic cells. Isotretinoin is a clinically effective short-term therapy for chronic or possibly for subacute cutaneous lupus erythematosus. The primary mechanism of action remains unestablished.

(Arch Dermatol 1986;122:170-176)

Author Affiliations
From the Departments of Dermatology (Drs Newton, Jorizzo, Solomon, and Sanchez), Pathology (Drs Solomon, Sanchez, and Cavallo), and Internal Medicine (Drs Daniels and Bell), University of Texas Medical Branch, Galveston.

Footnotes
Accepted for publication Aug 20, 1985.

Read before the Joint International Meeting of the Society for Investigative Dermatology and the Japanese Society for Investigative Dermatology, Washington, DC, May 3, 1985.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of Lupus Erythematosus
Housman et al.
Arch Dermatol 2003;139:50-54.
ABSTRACT | FULL TEXT  

Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations
Ting and Sontheimer
Lupus 2001;10:171-184.
ABSTRACT  

Efficiency of Acitretin in the Treatment of Cutaneous Lupus Erythematosus
Ruzicka et al.
Arch Dermatol 1988;124:897-902.
ABSTRACT